Although the number of samples was small, the double-positive expression of immunoreactive ERβ and p53 proteins may become a promising clinical parameter to predict the risk of lymph node metastasis and postoperative relapse. The gene discussed is ESR2; the disease is metastatic malignant neoplasm in the lymph nodes.